Histogenics Corporation
-
Biologics
Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer
WALTHAM, Mass., July 31, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Financial
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Hospitals
Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria
WALTHAM, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Recon
Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences
WALTHAM, Mass., Oct. 1, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Recon
Histogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer
WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Recon
Histogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Spine
Histogenics Corporation Announces World Class Scientific Advisory Board to Support Commercialization and Pipeline Development
WALTHAM, Mass., May 11, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More »